Exact Mass: 465.20860160000007

Exact Mass Matches: 465.20860160000007

Found 500 metabolites which its exact mass value is equals to given mass value 465.20860160000007, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Codonocarpine

C26H31N3O5 (465.2263596)

S9947

2-(Benzyloxycarbonylaminomethyl)biphenyl-2-carboxylic acid 2-(2-pyridyl)ethylamide

C29H27N3O3 (465.20523120000007)

Biotripyrrin-a

3-[(2E)-2-{[3-(2-carboxyethyl)-5-{[(2E)-3-ethenyl-4-methyl-5-oxo-2,5-dihydro-1H-pyrrol-2-ylidene]methyl}-4-methyl-1H-pyrrol-2-yl]methylidene}-4-methyl-5-oxo-2,5-dihydro-1H-pyrrol-3-yl]propanoic acid

C25H27N3O6 (465.18997620000005)

Biotripyrrin-a and biotripyrrin-b, bilirubin metabolites, are novel tripyrrole biocompounds and belong to a third group of bile pigments following biliverdin and bilirubin. They are regioisomers of each other. -- Yamaguchi T et al., J Biochem (Tokyo). 1994 Aug;116(2):298-303. PMID 7822247. These metabolites are recognized by an anti-bilirubin monoclonal antibody, 24G7, but are neg. in the diazo reaction. (PubMed ID 9836731 ). Biotripyrrin-a and biotripyrrin-b, bilirubin metabolites, are novel tripyrrole biocompounds and belong to a third group of bile pigments following biliverdin and bilirubin. They are regioisomers of each other. -- Yamaguchi T et al., J Biochem (Tokyo). 1994 Aug;116(2):298-303. PMID 7822247

Biotripyrrin-b

3-(2-{[(2Z)-3-(2-carboxyethyl)-5-hydroxy-4-methyl-2H-pyrrol-2-ylidene]methyl}-5-{[(2E)-4-ethenyl-5-hydroxy-3-methyl-2H-pyrrol-2-ylidene]methyl}-4-methyl-1H-pyrrol-3-yl)propanoate

C25H27N3O6 (465.18997620000005)

Acalabrutinib

4-{8-amino-3-[1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)benzamide

C26H23N7O2 (465.1913138)

Benzylpenicilloyl G

2-{[(5-carboxypentyl)-C-hydroxycarbonimidoyl][(1-hydroxy-2-phenylethylidene)amino]methyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxylate

C22H31N3O6S (465.19334660000004)

D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams

N-4-[2(R)-Amino-3-mercaptopropyl]amino-2-naphthylbenzoyl-(L)-leucine, TFA

2-({4-[(2-azaniumyl-3-sulfanylpropyl)amino]-2-(naphthalen-1-yl)phenyl}formamido)-4-methylpentanoate

C26H31N3O3S (465.20860160000007)

Luminespib

5-[2,4-dihydroxy-5-(propan-2-yl)phenyl]-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxamide

C26H31N3O5 (465.2263596)

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor

Notoamide K

C26H31N3O5 (465.2263596)

Delgramine

C27H31NO6 (465.2151266)

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-methylbutanamido]-3-carbamoylpropanamido]propanoic acid

C21H31N5O7 (465.2223376)

Tyr Val Gln Gly

2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-methylbutanamido]-4-carbamoylbutanamido]acetic acid

C21H31N5O7 (465.2223376)

Biotripyrrin-b

C25H27N3O6 (465.18997620000005)

Sarpogrelate Hydrochloride

C24H32ClNO6 (465.19180420000004)

D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist D006401 - Hematologic Agents > D005343 - Fibrinolytic Agents D050299 - Fibrin Modulating Agents D002317 - Cardiovascular Agents Sarpogrelate hydrochloride (MCI-9042) is a selective 5-HT2R antagonist, with pKis of 8.52, 6.57, and 7.43 for 5-HT2A, 5-HT2B, and 5-HT2C receptors, respectively. Sarpogrelate hydrochloride displays selectivity over 5-HT1, 5-HT3, 5-HT4, α1-, α2- and β-adrenoreceptor, histamine H1, H2 and muscarinic M3 receptors. Sarpogrelate hydrochloride can be used for the research of vascular disease associated with thrombosis[1][2][3].

TERT-BUTYL 5-((4-(TERT-BUTOXYCARBONYL)PIPERAZIN-1-YL)SULFONYL)-1H-INDOLE-1-CARBOXYLATE

C22H31N3O6S (465.19334660000004)

PF-543

Sphingosine Kinase 1 Inhibitor II

C27H31NO4S (465.19736860000006)

D004791 - Enzyme Inhibitors

4-METHOXYPHENYL 2-AMINO-3,6-DI-O-BENZYL-2-DEOXY-BETA-D-GLUCOPYRANOSIDE

C27H31NO6 (465.2151266)

11-(PYRENE-1-SULFONYLAMINO)UNDECANOIC ACID

C27H31NO4S (465.19736860000006)

2-CHLORO-5-NITROBENZAMIDE

C27H31NO4S (465.19736860000006)

Mebeverine hydrochloride

C25H36ClNO5 (465.22818760000007)

D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent D002491 - Central Nervous System Agents > D000927 - Anticonvulsants

Acalabrutinib

C26H23N7O2 (465.1913138)

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials, Guide to PHARMACOLOGY C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163774 - BTK-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D000970 - Antineoplastic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

2-Pyrrolidinone, 1-(4-O-β-D-galactopyranosyl-β-D-glucopyranosyl)-4-(2-methylpropyl)-, (4R)-

C20H35NO11 (465.221)

(1S,2R)-(-)-2-AMINOCYCLOHEX-3-ENECARBOXYLICACIDHYDROCHLORIDE

C27H31NO4S (465.19736860000006)

Carafiban

C24H27N5O5 (465.20120920000005)

CID 24906286

(2S)-2-[[[4-[[(2R)-2-amino-3-mercaptopropyl]amino]-2-(1-naphthalenyl)phenyl]-oxomethyl]amino]-4-methylpentanoic acid

C24H35NO6S (465.21849700000007)

YM-58790

C27H32ClN3O2 (465.2182922)

YM-58790 is a potent antagonist of mAChR. YM-58790 binds M1, M2, M3 with Ki values of 28 nM, 260 nM, and 15 nM. YM-58790 exhibits potent inhibitory activity on bladder pressuer in reflexly-evoked rhythmic contraction in rats[1].

n-(6-{2-[(3s,8as)-1-hydroxy-4-oxo-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-3-yl]acetyl}-2,2-dimethylchromen-5-yl)-2,2-dimethylbut-3-enamide

C26H31N3O5 (465.2263596)

1,22-dihydroxy-7,7-dimethyl-13-(2-methylbut-3-en-2-yl)-8-oxa-12,14,20-triazahexacyclo[11.10.0.0²,¹¹.0⁴,⁹.0¹⁴,²².0¹⁶,²⁰]tricosa-2,4(9),5,10-tetraene-15,21-dione

C26H31N3O5 (465.2263596)

(8e,22e)-27-methoxy-2-oxa-11,16,20-triazatricyclo[22.2.2.1³,⁷]nonacosa-1(26),3(29),4,6,8,10,20,22,24,27-decaene-4,10,21-triol

C26H31N3O5 (465.2263596)

(1r,13s,16s,22s,25s)-25-(hydroxymethyl)-7,7,26,26-tetramethyl-6,24-dioxa-12,14,20-triazaheptacyclo[11.10.3.0¹,¹³.0²,¹¹.0⁵,¹⁰.0¹⁴,²².0¹⁶,²⁰]hexacosa-2(11),3,5(10),8-tetraene-15,21-dione

(1r,13s,16s,22s,25s)-25-(hydroxymethyl)-7,7,26,26-tetramethyl-6,24-dioxa-12,14,20-triazaheptacyclo[11.10.3.0¹,¹³.0²,¹¹.0⁵,¹⁰.0¹⁴,²².0¹⁶,²⁰]hexacosa-2(11),3,5(10),8-tetraene-15,21-dione

C26H31N3O5 (465.2263596)

1,8a-dihydroxy-3-{[7-hydroxy-2,2-dimethyl-6-(2-methylbut-3-en-2-yl)chromeno[7,6-b]pyrrol-6-yl]methyl}-3h,6h,7h,8h-pyrrolo[1,2-a]pyrazin-4-one

C26H31N3O5 (465.2263596)

5-(acetyloxy)-4-ethylidene-6,7,14-trimethyl-3,8,17-trioxo-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-en-7-yl acetate

C23H31NO9 (465.19987160000005)

1,8a-dihydroxy-3-{[(6s)-7-hydroxy-2,2-dimethyl-6-(2-methylbut-3-en-2-yl)chromeno[7,6-b]pyrrol-6-yl]methyl}-3h,6h,7h,8h-pyrrolo[1,2-a]pyrazin-4-one

C26H31N3O5 (465.2263596)

5-{[(2e,6e,10s)-11-chloro-10-hydroxy-3,7,11-trimethyldodeca-2,6-dien-1-yl]oxy}-4,6-dimethoxy-3h-isoindol-1-ol

C25H36ClNO5 (465.22818760000007)

1,16-dihydroxy-7,7-dimethyl-13-(2-methylbut-3-en-2-yl)-6-oxa-12,14,20-triazahexacyclo[11.10.0.0²,¹¹.0⁵,¹⁰.0¹⁴,²².0¹⁶,²⁰]tricosa-2(11),3,5(10),8-tetraene-15,21-dione

C26H31N3O5 (465.2263596)